Keyphrases
Cryptococcal Meningitis
100%
COVID-19
43%
Cryptococcal Antigen
37%
Cerebrospinal Fluid
35%
Meningitis
29%
Cryptococcal Antigenemia
28%
Hydroxychloroquine
28%
Amphotericin B
23%
Advanced HIV Disease
22%
Cytomegalovirus Viremia
20%
Ugandan
19%
Uganda
19%
Randomized Clinical Trial
19%
Fluconazole
18%
Pre-exposure Prophylaxis (PrEP)
16%
AIDS/HIV
16%
Antigen Screening
16%
HIV Patients
15%
Clinical Trials
15%
Randomized Trial
15%
Titer
14%
Sub-Saharan Africa
14%
Cryptococcosis
13%
People Living with HIV (PLHIV)
12%
Cytomegalovirus
12%
Confidence Interval
11%
Early Fungicidal Activity
11%
Tuberculosis Diagnosis
11%
Non-HIV Cryptococcal Meningitis
11%
Liposomal Amphotericin B
11%
Virus Diseases
10%
Meningitis Diagnosis
10%
HIV-infected Adults
10%
Xpert MTB
10%
Central Nervous System
10%
C-reactive Protein
10%
Amphotericin B Deoxycholate
10%
Cryptococcus
10%
Lateral Flow Assay
9%
Minimum Inhibitory Concentration
8%
Tuberculosis
8%
HIV-associated
8%
Placebo
8%
Web-based
7%
United States
7%
Increased Mortality
7%
Mycobacterium Tuberculosis (M. tb)
7%
Mortality Factors
6%
Cryptococcus Neoformans
6%
Tuberculosis Meningitis
6%
Medicine and Dentistry
Cryptococcal Meningitis
82%
Human Immunodeficiency Virus
79%
Meningitis
32%
COVID-19
27%
Diseases
26%
Outpatient
24%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
Cerebrospinal Fluid
21%
Cytomegalovirus
20%
Viremia
20%
Infection
13%
Fluconazole
13%
Hydroxychloroquine
12%
Randomized Clinical Trial
12%
Virus Infection
12%
Amphotericin B
12%
Amphotericin
12%
Clinical Trial
11%
Lateral Flow Assay
11%
Cryptococcosis
11%
Leukocyte
9%
Randomized Controlled Trial
7%
Cerebrospinal Fluid Culture
6%
Placebo
6%
Diagnostic Performance
6%
Single Drug Dose
6%
Intracranial Pressure
6%
Cell Count
6%
Antifungal Therapy
5%
Hazard Ratio
5%
Central Nervous System
5%
Mycobacterium Tuberculosis
5%
Post-Exposure Prophylaxis
5%
Recurrent Disease
5%
Cluster Randomized Trial
5%
Immune Reconstitution Inflammatory Syndrome
5%
Dried Blood Spot
5%
Flucytosine
5%
Chloroquine
5%
Tuberculous Meningitis
5%
Lipoarabinomannan
5%
Puerperium
5%
Systematic Review
5%
Antifungal Susceptibility
5%
Sertraline
5%
Hyponatremia
5%
C Reactive Protein
5%
Visual Impairment
5%
Ophthalmoscopy
5%
Mydriatic Agent
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cryptococcal Meningitis
48%
Diseases
43%
HIV
35%
Coronavirinae
31%
Hydroxychloroquine
30%
Amphotericin B
24%
Clinical Trial
19%
SARS Coronavirus
17%
Amphotericin
17%
Randomized Clinical Trial
17%
Meningitis
16%
Fluconazole
14%
Infection
14%
Placebo
12%
Filobasidiella
12%
Cytomegalovirus
10%
Viremia
10%
C Reactive Protein
10%
Amphotericin B Deoxycholate
9%
Flucytosine
9%
Adverse Event
8%
Minimum Inhibitory Concentration
8%
Virus Infection
7%
Randomized Controlled Trial
7%
Tolerability
5%
Lipoarabinomannan
5%
Tuberculous Meningitis
5%
Sertraline
5%
Chloroquine
5%
Cryptococcus neoformans
5%
Bloodstream Infection
5%
